\nEuropean ombudsman questions European Medicines Agency over AbbVie redactions<\/font><\/strong><\/div>\nby Rory Watson<\/div>\nBritish Medical Journal.<\/font><\/strong> 2014 349:g6904.<\/div>\nThe European ombudsman, Emily O’Reilly, has written to the European Medicines Agency asking it to explain by 31 January 2015 the redactions it made in the clinical trial data provided by AbbVie for its best selling drug adalimumab [Humira], used to treat rheumatoid arthritis. The redactions were made as part of the settlement between the agency and the company after AbbVie had gone to court to try to prevent publication of certain clinical trial data.<\/p>\n
In her letter O’Reilly acknowledged that “certain redactions may be justified to protect the personal data of patients.” She also accepted that “certain other redactions, which mention the names of companies that provided services to AbbVie, or the names of software used by AbbVie, are not, in my view, problematic, as they may be considered to relate to the confidential business relationships of AbbVie.”<\/p>\n
But after examining the original and the redacted versions of the clinical trial data, internal agency communications, and correspondence between the agency and the company, she expressed “doubts and concerns as regards other redactions.” O’Reilly, who opened an investigation into the case in April, identified 16 instances where she wanted the agency to explain why the redactions were necessary to protect AbbVie’s legitimate commercial interests…<\/div>\n<\/blockquote>\n